

# Simvastatine + Bempedoïnezuur

M 8545

ESP15228: actieve metaboliet van bempedoïnezuur

| Onderbouwend             | Stof                          | Effect                                                                                                                                                                                                                                                                                                                     | Code |
|--------------------------|-------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|
| Spc + EPAR Nilemdo       | simvastatine + bempedoïnezuur | ↑AUC simvastatinezuur 2x (range 1.61-2.38x) en simvastatine 1.2x (range 0.94-1.52x) na simvastatine 40 mg 1x + bempedoïnezuur 180 mg in steady-stateconcentratie; studie met 12 subjects; zelfde resultaat met bempedoïnezuur 240 mg. Myositis met CPK >10x ULN is zelden gemeld met bempedoïnezuur en simvastatine 40 mg. | 2A   |
| Stockley online mei 2025 | simvastatine + bempedoïnezuur | getallen als SPC Nilemdo, obv data UK and US manufacturers; 'moderate, adjust, avoid concurrent use of simvastatin 20 mg or more'.                                                                                                                                                                                         | 1-2A |

| Overig                                                       | Stof                          | Effect                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
|--------------------------------------------------------------|-------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Spc + EPAR Nilemdo                                           | simvastatine                  | combinatie met simvastatine >40 mg/dag is geCI; bij combinatie moet de dosis simvastatine worden beperkt tot 20 mg per dag (of 40 mg per dag voor patiënten met ernstige hypercholesterolemie en een hoog risico op cardiovasculaire complicaties, die hun behandeldoel met een lagere dosis niet hebben bereikt en wanneer de voordelen naar verwachting opwegen tegen de potentiële risico's).<br>Mechanisme: bempedoïnezuur en de glucuronide zijn zwakke remmers van OATP1B1 en 1B3. Combinatie met substraten van OATP1B1 of OATP1B3 (oa simvastatine) kunnen leiden tot hogere plasmaconcentraties van deze geneesmiddelen. EPAR: statin Cmax were also increased by a similar extent, suggesting that not only the excretion but also the first pass effect of statins is affected. According to the applicant, the interaction can probably be attributed to inhibition of OATP transport. |
| Jadhav SB. Eur Heart J Cardiovasc Pharmacother 2022;8:578-6. | simvastatine + bempedoïnezuur | Dose-response models predicted that combining bempedoic acid with the lowest statin dose would achieve a similar degree of LDL-C lowering as quadrupling that statin dose; for example, the predicted LDL-C lowering was 42% with simvastatin 40 mg compared with 46% with simvastatin 10 mg + bempedoic acid 180 mg.<br>Methods: bempedoic acid and statin dosing and LDL-C data were pooled from clinical studies. Dose-response models were developed for bempedoic acid monotherapy and bempedoic acid-statin combinations using previously published statin parameters. Conclusion: these findings suggest bempedoic acid combined with lower statin doses offers similar LDL-C lowering compared with statin monotherapy at higher doses.                                                                                                                                                    |

## Opmerkingen

Werkgroep Interacties & MFB's: Ja/Ja. Na veel discussie besloten geen afkappunt voor dosis simvastatine te hanteren. In advies doseerinfo uit SPC overnemen, of overstappen op een andere statine.

PubMed: verder niets, behalve Jadhav 2022.

|                |                                              |
|----------------|----------------------------------------------|
| Risicofactoren | hoge dosis statine, spierpijn of verhoogd CK |
|----------------|----------------------------------------------|

|                  | Interactie | Actie | Datum  |
|------------------|------------|-------|--------|
| Beslissing WG IA | Ja         | Ja    | 2-6-25 |